Autophagy inhibition contributes to Endostar sensitization in esophageal squamous cell carcinoma.

Autophagy inhibition contributes to Endostar sensitization in esophageal squamous cell carcinoma.
复制标题

DOI:
10.3892/ol.2017.7017
复制
发表时间:
2017-12
期刊:
影响因子:
2.9
通讯作者:
Xu J
Xu J
中科院分区:
医学4区
文献类型:
--
作者:
Han X;Wang Z;Hu B;Xu J

文献摘要

参考文献

被引文献

相似文献

Endostar是一种新型的人工合成的抗血管生成药物,已获准临床使用。以前的研究表明,食道癌患者可以受益于Endostar联合化疗或放化疗。然而,这种药物的最有利用途仍有待阐明。自噬在癌症治疗中的作用仍然存在争议。目前的研究结果表明,Endostar促进自噬激活,这种激活是通过抑制血管内皮生长因子、AKT丝氨酸/苏氨酸激酶下游信号分子的磷酸化和雷帕霉素信号通路的机械靶点来调节的。此外,与Endostar单药治疗相比,使用药物抑制剂氯喹抑制自噬有助于Endostar的抗增殖作用和增加凋亡细胞的数量。综上所述,本研究结果表明,Endostar诱导的自噬激活在人食道癌的治疗中起到保护作用,抑制自噬可以促进Endostar的抗增殖作用。因此,联合应用Endostar和自噬抑制剂可能是提高Endostar治疗食道癌患者疗效的一种新的有前景的方法。
Endostar is a novel artificially-synthesized anti-angiogenesis drug, and has been approved for clinical use. Previous studies have indicated that patients with esophageal cancer could benefit from Endostar combined with chemotherapy or chemoradiotherapy. However, the most advantageous use of this drug remains to be elucidated. The role of autophagy in cancer treatment remains controversial. The results of the present study demonstrated that Endostar promotes autophagy activation, which is regulated via phosphorylation inhibition of the downstream signaling molecules of the vascular endothelial growth factor, AKT serine/threonine kinase and mechanistic target of rapamycin signaling pathways. Furthermore, inhibiting autophagy using the pharmacological inhibitor chloroquine facilitated the antiproliferative effect of Endostar and increased the number of apoptotic cells, compared with Endostar monotherapy. Taken together, the results of the present study suggest that autophagy activation induced by Endostar serves a protective role in human esophageal cancer treatment, and that autophagy inhibition promotes the antiproliferative role of Endostar. Therefore, the combination of Endostar with an autophagy inhibitor may be a novel prospective approach to improving the efficacy of Endostar for the treatment of patients with esophageal cancer.
DOI: 10.3322/caac.21208
发表时间: 2014-01-01
影响因子: 254.7
作者:
Siegel, Rebecca;Ma, Jiemin;Jemal, Ahmedin
通讯作者: Jemal, Ahmedin
DOI: 10.14670/hh-18.715
发表时间: 2003-07-01
影响因子: 2
作者:
Chau, YP;Lin, SY;Tai, MH
通讯作者: Tai, MH
DOI: 10.1038/sj.bjp.0704367
发表时间: 2001-11-01
影响因子: 7.3
作者:
Bernatchez, PN;Allen, BG;Sirois, MG
通讯作者: Sirois, MG
DOI: 10.1016/j.ejphar.2009.04.032
发表时间: 2009-07-01
影响因子: 5
作者:
Ni, Qinggui;Ji, Hui;Xu, Chengyun
通讯作者: Xu, Chengyun
DOI: 10.3892/br.2012.3
发表时间: 2013-01-01
期刊: BIOMEDICAL REPORTS
影响因子: 2.3
作者:
Wang, Yu-Bin;Liu, Jun-Hong;Song, Zong-Min
通讯作者: Song, Zong-Min